[1] Sung H, Ferlay J, Siegel R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2021,71(3):209-249.
[2] Llovet J M, Kelley R K, Villanueva A, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021,7(1):6.
[3] Burki T. WHO′s 2024 global hepatitis report[J]. Lancet Infect Dis,2024,24(6):e362-e363.
[4] Pavlovic N, Rani B, Gerwins P, et al. Platelets as key factors in hepatocellular carcinoma[J]. Cancers,2019,11(7):1022.
[5] Cuesta A M, Palao N, Bragado P, et al. New and old key players in liver cancer[J]. Int J Mol Sci,2023,24(24):17152.
[6] Zhang Q, Shi B, Wu L. Characteristics and risk factors of infections in patients with HBV-related acute-on-chronic liver failure: a retrospective study[J]. PeerJ,2022,10:e13519.
[7] Fan Z, Wu M, Tang Z, et al. Predictive value of platelet-related measures in patients with hepatocellular carcinoma[J]. Technol Cancer Res Treat,2022,21:15330338211064414.
[8] Yu J I, Park H C, Yoo G S, et al. Clinical importance of the absolute count of neutrophils, lymphocytes, monocytes, and platelets in newly diagnosed hepatocellular carcinoma[J]. Sci Rep,2021,11(1):2614.
[9] Lee H W, Park S Y, Lee M, et al. An optimized hepatocellular carcinoma prediction model for chronic hepatitis B with well-controlled viremia[J]. Liver Int,2020,40(7):1736-1743.
[10] Chun H S, Papatheodoridis G V, Lee M, et al. PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B[J]. J Hepatol,2024,80(1):20-30.
[11] Sinn D H, Kim S E, Kim B K, et al. The risk of hepatocellular carcinoma among chronic hepatitis B virus-infected patients outside current treatment criteria[J]. J Viral Hepat, 2019,26(12):1465-1472.
[12] Kim S U, Chon Y E, Seo Y S, et al. A multi-centre study of trends in hepatitis B virus-related hepatocellular carcinoma risk over time during long-term entecavir therapy[J]. J Viral Hepat,2020,27(12):1352-1358.
[13] Liu K, Huang Z, Yang S, et al. The age, gamma-glutamyl transpeptidase and platelet index: a novel noninvasive model for predicting hepatocellular carcinoma in patients with hepatitis B virus-related liver cirrhosis[J]. J Hepatocell Carcinoma,2022,9:1057-1063.
[14] Mao H, Zheng S, Yang S, et al. A new model predicts hepatocellular carcinoma in patients with HBV-related decompensated liver cirrhosis and long-term antiviral therapy: a prospective study[J]. PeerJ, 2023,11:e15014.
[15] Peng W, Li C, Zhang X, et al. The impact of thrombocytopenia on prognosis of HBV-related small hepatocellular carcinoma: a propensity score matching analysis[J]. World J Surg Oncol,2021,19(1):46.
[16] Wu C, Chau G, Lee I, et al. Early and late recurrence of surgically resected hepatitis B virus-related hepatocellular carcinoma on nucleos(t)ide analogues therapy[J]. J Formos Med Assoc,2021,120(8):1563-1571.
[17] Huang R, Zheng Y, Zou W, et al. Blood biomarkers predict survival outcomes in patients with hepatitis B virus-induced hepatocellular carcinoma treated with PD-1 inhibitors[J]. J Immunol Res,2022,2022:3781109.
[18] Yang Y, Wang M C, Tian T, et al. A high preoperative platelet-lymphocyte ratio is a negative predictor of survival after liver resection for hepatitis B virus-related hepatocellular carcinoma: a retrospective study[J]. Front Oncol,2020,10:576205.
[19] Zheng X, Ye B, Gou Y, et al. Neutrophil to lymphocyte and platelet to lymphocyte ratios as biomarkers to predict relapse and survival in posthepatectomy HBV-related hepatocellular carcinoma: a meta-analysis and preliminary immune perspective[J]. Transl Cancer Res,2021,10(3):1261-1272.
[20] Wenpei G, Yuan L, Liangbo L, et al. Predictive value of preoperative inflammatory indexes for postoperative early recurrence of hepatitis B-related hepatocellular carcinoma[J]. Front Oncol,2023,13:1142168.
[21] Yao Y, Zhang M, Liu D, et al. Changes in systemic immune-inflammation index (SII) predict the prognosis of patients with hepatitis B-related hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors[J]. Clin Transl Oncol,2025, 27(3):1155-1165.
[22] Zhang C, Wu J, Xu J, et al. Association between aspartate aminotransferase-to-platelet ratio index and hepatocellular carcinoma risk in patients with chronic hepatitis: a meta-analysis of cohort study[J]. Dis Markers,2019,2019:2046825.
[23] Lai L, Su T, Liang Z, et al. Development and assessment of novel predictive nomograms based on APRI for hepatitis B virus-associated small solitary hepatocellular carcinoma with stereotactic body radiotherapy[J]. J Cancer,2020,11(22):6642-6652.
[24] Han Y, Liu J, Pan J, et al. Prognosis and risk factors of recurrence in HBV-related small hepatocellular carcinoma after stereotactic body radiation therapy[J]. Front Oncol,2022,12:903355.
[25] Mai R Y, Wang Y Y, Bai T, et al. Combination of AlbI and APRI to predict post-hepatectomy liver failure after liver resection for HBV-related HCC patients[J]. Cancer Manag Res,2019,11:8799-8806.
[26] Dai T, Deng M, Ye L, et al. Prognostic value of combined preoperative gamma-glutamyl transpeptidase to platelet ratio and fibrinogen in patients with HBV-related hepatocellular carcinoma after hepatectomy[J]. Am J Transl Res,2020,12(6):2984-2997.
[27] 梅宝富, 邓志锋, 郑兰, 等. γ-谷氨酰转肽酶和血小板比值对肝癌介入术后急性肝功能恶化的预测作用[J]. 肝脏, 2021,26(2):175-178.
[28] Seong G, Sinn D H, Kang W, et al. Age and fibrosis index for the prediction of hepatocellular carcinoma risk in patients with high hepatitis B virus DNA but normal alanine aminotransferase[J]. Eur J Gastroenterol Hepatol,2022,34(1):69-75.
[29] Tseng T C, Choi J, Nguyen M H, et al. One-year fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment[J]. Hepatol Int,2021,15(1):105-113.
[30] Kuwano A, Miyazaki M, Yada M, et al. FIB-4 index and serum alpha-fetoprotein are useful predictors of hepatocellular carcinoma occurrence in hepatitis B patients with nucleos(t)ide analogs therapy[J]. Exp Ther Med,2023,26(3):441.
[31] Luo J, Yuan M, Li S, et al. Dynamic evaluation of liver fibrosis to assess hepatocellular carcinoma risk in patients with chronic hepatitis B receiving nucleoside analogs treatment[J]. Rev Inst Med Trop Sao Paulo,2024,66:e27.
[32] Tsai M Y, Yen Y H, Huang P Y, et al. The pre- and postoperative FIB-4 indexes are good predictors to the outcomes of HBV-related HCC patients after resection[J]. Gastroenterol Res Pract,2019,2019:8945798.
[33] Gao T M, Jin S J, Fang F, et al. Novel preoperative type IV collagen to predict the risk of hepatocellular carcinoma in patients with hepatitis B virus-related cirrhotic portal hypertension after laparoscopic splenectomy and azygoportal disconnection[J]. J Hepatocell Carcinoma,2023,10:2411-2420. |
